Business Wire

Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis

Jaa

Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190416005296/en/

Under the terms of the three-year collaboration, insitro’s proprietary platform will be utilized to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease. The insitro Human (ISH) platform applies machine learning, human genetics and functional genomics to generate and optimize unique in vitro models and drive therapeutic discovery and development. The ISH platform will provide insights into disease progression, suggest candidate targets, and predict patient responses to potential therapeutic interventions. Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.

“Gilead is committed to researching and developing treatments for patients living with NASH, particularly those with advanced fibrosis who have the greatest unmet need,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “We are excited about the opportunity to partner with insitro to tackle the scientific challenges associated with this complex disease. Through this collaboration we will utilize deep learning to explore the scientific underpinnings of the biology and clinical spectrum of NASH, with the goal of accelerating the development of highly effective treatment options for patients with this disease.”

“NASH is a progressive liver disease that can lead to fibrosis, cirrhosis, and liver cancer and will soon be the predominant cause of liver transplantation in the U.S.,” said Daphne Koller, Ph.D., CEO and founder of insitro. “We are excited to work with Gilead, a leader in liver disease, in bringing to bear novel tools toward identifying new therapeutics for NASH and helping the many patients in need around the world.”

Under the terms of the agreement, insitro will receive an upfront payment of $15 million, with additional near-term payments up to $35 million based on operational milestones. insitro will be eligible to receive up to $200 million for the achievement of preclinical, development, regulatory and commercial milestones for each of the five Gilead targets; and up to low double-digit tiered royalties on net sales. For programs where insitro opts in, it will have the right to co-develop and co-detail in the U.S., receive a profit share in China and receive milestone payments and royalties on other ex-U.S. sales.

About NASH

Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH.

About insitro

insitro is a data-driven drug discovery and development company that uses machine learning to transform the way that drugs are discovered and delivered to patients. By generating high-throughput, functional genomic data sets that align with patient data, and interpreting those data via novel machine learning methods, insitro builds predictive models that can accelerate target selection and the design of effective therapeutics. The company is building a high-throughput bio-data factory based on state-of-the-art technologies from bioengineering, allowing the creation of large data sets that enable cutting edge machine learning methods to be brought to bear on key bottlenecks in drug development. insitro was launched in 2018 with a Series A of over $100M funded by a16z, Arch Venture Partners, Foresite Capital, GV (formerly Google Ventures), and Third Rock Ventures, as well as additional investments from Alexandria Venture Investments, Bezos Expeditions, Mubadala Investment Company, Two Sigma Ventures, Verily and other undisclosed investors. The company is located in South San Francisco, CA. For more information on insitro, please visit the company’s website at www.insitro.com.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Gilead Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration and Gilead may fail to develop and/or commercialize any product candidates from this collaboration. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Gilead Contacts
Investors:
Sung Lee
+1 650-524-7792
Media:
Arran Attridge
+1 650-425-8975

insitro Contacts
Investors:
ir@insitro.com
Media:
Dan Budwick, 1AB
dan@1abmedia.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

BrandSafway Selects Rimini Street Application Management Services for Salesforce26.6.2019 16:00:00 EESTTiedote

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that BrandSafway, a global leader in access, industrial services and forming and shoring solutions for the industrial, commercial and infrastructure markets, has selected Rimini Street Application Management Services (AMS) for Salesforce for its Salesforce Sales Cloud system. BrandSafway has been leveraging Rimini Street support for its Oracle Database, E-Business Suite and JD Edwards software products since 2014, and now, BrandSafway is expanding its support service scope with Rimini Street to maximize the value and business impact of Salesforce and the Salesforce Sales Cloud system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005022/en/ BrandSafway Selects Rimini Street Application Management Servi

Modern Governance 4.0: Global Compliance Is Now Integrated with the World’s Leading Board Platform26.6.2019 16:00:00 EESTTiedote

With its second major product announcement this week, Diligent today introduced the integration of its trusted entity management technology into the Governance Cloud with new powerful reporting and dashboard functionality. Diligent Entities, formerly Blueprint OneWorld, greatly improves transparency and decreases the burden and risks for subsidiary and entity management in a fast-paced, digital environment. This launch positions Diligent as the first of its kind to provide a holistic technology platform that can power modern governance, offering leadership and the board the most effective tools – from a board portal to secure file sharing to entity compliance – accessible in one place. Business today is global and decentralized, adding layers of regulatory and ethical compliance complexity. Such distributed business interests – with various entities and subsidiaries – are often spread across multiple jurisdictions and subject to increasing regulatory obligations that make reporting and

Jabil Packaging Solutions Launches New Sustainable Packaging Services; Accelerates Sustainable Packaging Innovation26.6.2019 15:45:00 EESTTiedote

Jabil Packaging Solutions (JPS), a division of Jabil Inc. (NYSE: JBL), today introduced a new suite of Sustainable Packaging Services , that enable packaged goods brands to design and deliver innovative new sustainable packaging formats into the marketplace at speed. Today, companies producing Consumer Packaged Goods (CPG) are at a turning point. They must find smart ways to make their products and packaging sustainable or face increasing regulations, taxes and pushback from consumers. Companies are trying to respond to sustainability mandates and want to do the right thing for the environment. Yet assessing what is needed, sourcing the right materials and designing products that meet their corporate sustainability goals is extremely complex due to the interdependencies and expertise required for end-to-end sustainable development. “For CPGs, there has never been a bigger challenge than the transition to a truly sustainable business model,” said Jason Paladino, JPS Vice President of Te

Moody’s Analytics Wins Enterprise-Wide Stress Testing Product of the Year at Risk Technology Awards26.6.2019 13:00:00 EESTTiedote

Moody’s Analytics, a global provider of financial intelligence, has won Enterprise-Wide Stress Testing Product of the Year at the 2019 Risk Technology Awards. It’s one of six categories won across finance, accounting, regulatory, and credit functions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005246/en/ Traditionally, stress testing exercises have required the participation of many groups within an institution and often took several months to complete. Today, banks must be able to respond to regulatory and management requests faster, while also extracting business value from the results. Moody’s Analytics helps banks overcome the challenges of stress testing. Our solutions improve data quality and integrity and make efficient use of resource and technology investments, while delivering industry-leading Moody’s Analytics modeling expertise. “Stress testing plays a critical role in how banks manage risk. Understandi

Tech Giant Alibaba Cloud Partners With UAE’s Group 42 to Host First MEA Internet Summit26.6.2019 12:19:00 EESTTiedote

Alibaba Cloud, the data intelligence backbone of Alibaba Group, today held its inaugural Middle East and Africa (MEA) Internet Summit in partnership with UAE-based Artificial Intelligence (AI) and Cloud Computing leader Group 42. Drawing the participation of tech experts and executives from the region’s top 100 internet companies, the summit took place during the Ghyma Conference 2019. Among the distinguished guests were HE Saif Mohammed Al Hajri, Chairman of the Department of Economic Development Abu Dhabi, His Excellency Mohammed Gheyath, Executive Director Information Security Operations, Abu Dhabi Digital Authority, Ibrahim Ajami, Head of Mubadala Ventures, Peng Xiao, CEO of Group 42, and Selina Yuan, President of Alibaba Cloud Intelligence International. Panelists and speakers covered an extensive range of topics over 10 keynote speeches. These included maximising the potential of cloud and AI, leveraging the internet to thrive in the new digital age, taking e-commerce to the next

SIGMOLECS®: the Most Advanced Technology Available for Regenerative Medicine26.6.2019 12:00:00 EESTTiedote

Contrad Swiss, a pharmaceutical company focused on breakthrough, innovative products that reframe the world of medicine, announces a new partnership with Dr JO Serrentino to bring to the market effective biomedical remedies unlike any other. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005031/en/ Photo by Contrad Swiss SIGMOLECS® Technology was conceived and engineered by Dr Serrentino exclusively for Contrad Swiss. SIGMOLECS® uses the highest bioavailable signaling molecules to summon and target biological pathways for precise programming at the cellular level. The result is like a program code of the cells, deploying them to organize into specific patterns. SIGMOLECS® talks to the cells in their language. ACTV8SKN® – Actuator - contains the exclusive SIGMOLECS® Technology. ACTV8SKN® is an odorless fluid gel of peptide-bonded amino acids, specifically engineered for a complete signaling spectrum that awakens cell cy

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme